ANNOUNCEMENT TO SUPPORT NEW COMBINED ANNUAL ACCOUNTING
Due to changes in international regulation, we were forced to radically reorganize the company's strategy and structure.
Consolidation with Russian assets has been postponed to a time when regulations and the international situation will allow such an operation.
In connection with this decision, Russian assets were excluded from the combined statements in order not to mislead investors and to conduct an audit of the company’s statements (while retaining Russian assets, such an audit is currently impossible). In addition to Rafarma, the combined reporting includes the following organizations that are in the process of joining Rafarma:
The company's focus has shifted to the aggressive development, production and organization of supplies of medical equipment, primarily for nuclear medicine - this is done by Noya Therapeutics Limited (Hong Kong). Over the past few years, this company has also been implementing a project to develop and implement “Smart” packaging for medicines in the world.
Noya Therapeutics Ltd. (Israel) was registered as a private limited liability company whose shares are registered in Israel, registration number 516743473. Currently, in this company we have concentrated our main investments in the development of radiopharmaceuticals, reselling to it our existing technological projects and know-how.
Our goal is to concentrate all innovative developments in the field of drugs and isotopes in it.
Raivo Unt
03/26/2024